JP2022535127A5 - - Google Patents

Info

Publication number
JP2022535127A5
JP2022535127A5 JP2021572103A JP2021572103A JP2022535127A5 JP 2022535127 A5 JP2022535127 A5 JP 2022535127A5 JP 2021572103 A JP2021572103 A JP 2021572103A JP 2021572103 A JP2021572103 A JP 2021572103A JP 2022535127 A5 JP2022535127 A5 JP 2022535127A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
dose
approximately
aat rnai
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021572103A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535127A (ja
JP7697889B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/036359 external-priority patent/WO2020247774A1/en
Publication of JP2022535127A publication Critical patent/JP2022535127A/ja
Publication of JP2022535127A5 publication Critical patent/JP2022535127A5/ja
Priority to JP2025039288A priority Critical patent/JP2025096283A/ja
Application granted granted Critical
Publication of JP7697889B2 publication Critical patent/JP7697889B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021572103A 2019-06-06 2020-06-05 アルファ-1アンチトリプシン欠乏症(aatd)の治療法 Active JP7697889B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025039288A JP2025096283A (ja) 2019-06-06 2025-03-12 アルファ-1アンチトリプシン欠乏症(aatd)の治療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962858059P 2019-06-06 2019-06-06
US62/858,059 2019-06-06
PCT/US2020/036359 WO2020247774A1 (en) 2019-06-06 2020-06-05 Methods for the treatment of alpha-1 antitrypsin deficiency (aatd)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025039288A Division JP2025096283A (ja) 2019-06-06 2025-03-12 アルファ-1アンチトリプシン欠乏症(aatd)の治療法

Publications (3)

Publication Number Publication Date
JP2022535127A JP2022535127A (ja) 2022-08-04
JP2022535127A5 true JP2022535127A5 (https=) 2023-06-13
JP7697889B2 JP7697889B2 (ja) 2025-06-24

Family

ID=73652297

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021572103A Active JP7697889B2 (ja) 2019-06-06 2020-06-05 アルファ-1アンチトリプシン欠乏症(aatd)の治療法
JP2025039288A Pending JP2025096283A (ja) 2019-06-06 2025-03-12 アルファ-1アンチトリプシン欠乏症(aatd)の治療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025039288A Pending JP2025096283A (ja) 2019-06-06 2025-03-12 アルファ-1アンチトリプシン欠乏症(aatd)の治療法

Country Status (12)

Country Link
US (1) US12582668B2 (https=)
EP (1) EP3980540A4 (https=)
JP (2) JP7697889B2 (https=)
KR (1) KR20220019255A (https=)
CN (1) CN114222820A (https=)
AU (1) AU2020286462A1 (https=)
BR (1) BR112021024534A2 (https=)
CA (1) CA3141762A1 (https=)
CO (1) CO2022000016A2 (https=)
MX (1) MX2021015003A (https=)
TW (1) TW202113081A (https=)
WO (1) WO2020247774A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α-1抗胰蛋白酶基因表現之組合物及方法
CN110268060B (zh) 2017-01-10 2024-07-26 箭头药业股份有限公司 α-1抗胰蛋白酶(AAT)RNAi物质、包含AAT RNAi物质的组合物和使用方法
MX2021015003A (es) 2019-06-06 2022-01-24 Arrowhead Pharmaceuticals Inc Metodos para el tratamiento de la deficiencia de alfa-1 antitripsina (aatd).
JP7846095B2 (ja) * 2020-09-15 2026-04-14 アローヘッド ファーマシューティカルズ インコーポレイテッド Z-aatタンパク質のレベルを低下させる方法
EP4392556A1 (en) * 2021-08-25 2024-07-03 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting ?lpha-1 antitrypsin expression
CA3264922A1 (en) * 2022-08-22 2024-02-29 Arrowhead Pharmaceuticals, Inc. METHODS FOR THE TREATMENT OF DISEASES AND DISORDERS RELATED TO ANGPTL3
WO2025219443A1 (en) * 2024-04-19 2025-10-23 Uniqure Biopharma B.V. Nucleic acid for a1at regulation

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
EP0366685B1 (en) 1987-06-24 1994-10-19 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
DE69034150T2 (de) 1989-10-24 2005-08-25 Isis Pharmaceuticals, Inc., Carlsbad 2'-Modifizierte Oligonukleotide
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5212295A (en) 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
DE69233046T2 (de) 1991-10-24 2004-03-04 Isis Pharmaceuticals, Inc., Carlsfeld Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US6077705A (en) 1996-05-17 2000-06-20 Thomas Jefferson University Ribozyme-mediated gene replacement
US6172209B1 (en) 1997-02-14 2001-01-09 Isis Pharmaceuticals Inc. Aminooxy-modified oligonucleotides and methods for making same
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
JP4236812B2 (ja) 1997-09-12 2009-03-11 エクシコン エ/エス オリゴヌクレオチド類似体
FR2774379B1 (fr) 1998-01-30 2002-03-29 Groupe Limagrain Holding Procede de production, par des cellules vegetales, d'alpha 1-antitrypsine et de ses variantes, et produits contenant l'alpha-antitrypsine ainsi obtenue
US6271358B1 (en) 1998-07-27 2001-08-07 Isis Pharmaceuticals, Inc. RNA targeted 2′-modified oligonucleotides that are conformationally preorganized
ES2234563T5 (es) 1999-02-12 2018-01-17 Daiichi Sankyo Company, Limited Nuevos análogos de nucleósidos y oligonucleótidos
DE60040274D1 (de) 1999-03-10 2008-10-30 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
CA2429814C (en) 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
US20050137153A1 (en) * 2002-02-20 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA)
AU2003295600A1 (en) 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
ATE443765T1 (de) 2003-03-21 2009-10-15 Santaris Pharma As Analoga kurzer interferierender rna (sirna)
US8053232B2 (en) 2004-01-23 2011-11-08 Virxsys Corporation Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing
CA2559955C (en) 2004-03-15 2016-02-16 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
AU2005327506B2 (en) * 2004-10-20 2010-07-08 Antisense Therapeutics Ltd Antisense modulation of integrin alpha4 expression
WO2008016391A2 (en) 2006-01-31 2008-02-07 The Board Of Trustees Of The Leland Stanford Junior University Self-complementary parvoviral vectors, and methods for making and using the same
CN101500548A (zh) 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
WO2008086524A2 (en) 2007-01-11 2008-07-17 University Of Florida Research Foundation, Inc. Alpha-1-antitrypsin variants and uses thereof
KR101629017B1 (ko) 2007-05-22 2016-06-10 아크투루스 쎄라퓨틱스, 인크. 히드록시메틸 치환된 rna 올리고뉴클레오티드 및 rna 복합체
WO2009073809A2 (en) 2007-12-04 2009-06-11 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
CA2718765A1 (en) 2008-03-20 2009-09-24 Quark Pharmaceuticals, Inc. Novel sirna compounds for inhibiting rtp801
KR101728655B1 (ko) 2008-12-18 2017-04-19 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
SI2539451T1 (sl) 2010-02-24 2016-04-29 Arrowhead Research Corporation Sestavki za ciljano dostavo sirna
AU2011299233B2 (en) 2010-09-07 2016-09-15 Integrated Dna Technologies, Inc. Modifications for antisense compounds
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
CA3131967A1 (en) 2010-12-29 2012-07-05 F. Hoffman-La Roche Ag Small molecule conjugates for intracellular delivery of nucleic acids
WO2012178033A2 (en) 2011-06-23 2012-12-27 Alnylam Pharmaceuticals, Inc. Serpina1 sirnas: compositions of matter and methods of treatment
WO2013032829A1 (en) 2011-08-26 2013-03-07 Arrowhead Research Corporation Poly(vinyl ester) polymers for in vivo nucleic acid delivery
US9340784B2 (en) 2012-03-19 2016-05-17 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating alpha-1-antitrypsin expression
CA2842041A1 (en) 2012-04-18 2013-10-24 Arrowhead Research Corporation Poly(acrylate) polymers for in vivo nucleic acid delivery
EA038792B1 (ru) 2013-05-22 2021-10-20 Элнилэм Фармасьютикалз, Инк. КОМПОЗИЦИИ НА ОСНОВЕ RNAi Serpina1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2014197524A2 (en) 2013-06-06 2014-12-11 Serpin Pharma, Llc Peptide therapy for treatment of alpha-1 antitrypsin deficiency and associated pathologies
US9458457B2 (en) 2013-07-03 2016-10-04 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
CA2950960A1 (en) 2014-06-06 2015-12-10 Solstice Biologics, Ltd. Polynucleotide constructs having bioreversible and non-bioreversible groups
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α-1抗胰蛋白酶基因表現之組合物及方法
AU2016306275A1 (en) 2015-08-07 2018-02-08 Arrowhead Pharmaceuticals, Inc. RNAi therapy for Hepatitis B virus infection
WO2017139616A1 (en) 2016-02-10 2017-08-17 Arrowhead Pharmaceuticals, Inc. Methods of treatment for alpha-1 antitrypsin deficiency
CA3011946A1 (en) 2016-03-07 2017-09-14 Arrowhead Pharmaceuticals, Inc. Targeting ligands for therapeutic compounds
EP3469083A1 (en) * 2016-06-10 2019-04-17 Alnylam Pharmaceuticals, Inc. COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
SG11201901841TA (en) 2016-09-02 2019-03-28 Arrowhead Pharmaceuticals Inc Targeting ligands
TWI788312B (zh) 2016-11-23 2023-01-01 美商阿尼拉製藥公司 絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
CN110268060B (zh) 2017-01-10 2024-07-26 箭头药业股份有限公司 α-1抗胰蛋白酶(AAT)RNAi物质、包含AAT RNAi物质的组合物和使用方法
SE1750774A1 (en) 2017-06-19 2018-12-11 Hepgene Medical Ab Novel nucleic acid molecules and their use in therapy
MX2021015003A (es) 2019-06-06 2022-01-24 Arrowhead Pharmaceuticals Inc Metodos para el tratamiento de la deficiencia de alfa-1 antitripsina (aatd).
JP7846095B2 (ja) 2020-09-15 2026-04-14 アローヘッド ファーマシューティカルズ インコーポレイテッド Z-aatタンパク質のレベルを低下させる方法

Similar Documents

Publication Publication Date Title
JP2022535127A5 (https=)
JP2025096283A5 (https=)
JP2020073546A5 (https=)
JP2022180461A5 (https=)
JP2011500851A5 (https=)
HRP20241051T1 (hr) Premošteni spojevi tricikličkog karbamoilpiridona i njihove uporabe
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
JP2005501110A5 (https=)
JP2013541583A (ja) 組み合わせ組成物
JP2002528502A5 (https=)
JP2017514911A5 (https=)
JP2005508963A5 (https=)
CN110139668A (zh) 一种预防和治疗肝纤维化的方法
CL2024003616A1 (es) Composición farmacéutica oral y uso para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2009506978A5 (https=)
JP2020510043A5 (https=)
JP2023541170A5 (https=)
RU2002105485A (ru) Применение микофенолята мофетила в сочетании с ПЭГ-интерфероном-α (ПЭГ-IFN-α)
JP2007501806A5 (https=)
JP2024540439A5 (https=)
JP2023020885A5 (https=)
RU2021139235A (ru) Способы лечения дефицита альфа-1-антитрипсина (aatd)
JP2000507207A (ja) 複合注射剤
JP2019178177A5 (https=)
JP2024543347A5 (https=)